Breast sarcomas: Current and future perspectives

Breast

Volumn 20, Issue 3, 2011, Pages 199-204

  Voutsadakis, Ioannis A ^a   Zaman, Khalil ^a   Leyvraz, Serge ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Breast; Molecular lesions; Post irradiation sarcomas; Sarcoma; Targeted therapies

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; DASATINIB; DOCETAXEL; DOXORUBICIN; ERIBULIN; EVEROLIMUS; FIGITUMUMAB; GEMCITABINE; IFOSFAMIDE; IMATINIB; NAVELBINE; PACLITAXEL; PALIFOSFAMIDE; PAZOPANIB; PROTEIN P53; SOMATOMEDIN B; SOMATOMEDIN C; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRABECTEDIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADVANCED CANCER; ANGIOSARCOMA; ANTINEOPLASTIC ACTIVITY; BREAST CARCINOMA; BREAST SARCOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CHROMOSOME TRANSLOCATION; DRUG EFFICACY; EWING SARCOMA; FIBROSARCOMA; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; KIDNEY CARCINOMA; LEIOMYOSARCOMA; LIPOSARCOMA; METASTASIS; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SARCOMA; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; TREATMENT PLANNING; TUMOR BIOPSY;

EID: 79957709094     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2011.02.016     Document Type: Review

References (82)

1. Karim R.Z., Scolyer R.A., Tse G.M., Tan P.-H., Putti T.C., Lee C.S. Pathogenic mechanisms in the initiation and progression of mammary phyllodes tumours. Pathol 2009, 41:105-117.
2. Adem C., Reynolds C., Ingle J.N., Nascimento A.G. Primary breast sarcoma: clinicopathologic series from the Mayo Clinic and review of the literature. Br J Cancer 2004, 91:237-241.
3. McGowan T.S., Cummings B.J., O'Sullivan B., Catton C.N., Miller N., Panzarella T. An analysis of 78 breast sarcoma patients without distant metastases at presentation. Int J Rad Oncol Biol Phys 2000, 46:383-390.
4. Bousquet G., Confavreux C., Magné N., Tunon de Lara C., Poortmans P., Senkus E., et al. Outcome and prognostic factors in breast sarcoma: a multicenter study from the rare cancer network. Radiother Oncol 2007, 85:355-361.
5. Pandey M., Mathew A., Abraham E.K., Rajan B. Primary sarcoma of the breast. J Surg Oncol 2004, 87:121-125.
6. Fields R.C., Aft R.L., Gillanders W.E., Eberlein T.J., Margenthaler J.A. Treatment and outcomes of patients with primary breast sarcoma. Am J Surg 2008, 196:559-561.
7. Confavreux C., Lurkin A., Mitton N., Blondet R., Saba C., Ranchère D., et al. Sarcomas and malignant phyllodes tumours of the breast - a retrospective study. Eur J Cancer 2006, 42:2715-2721.
8. Balzer B.L., Weiss S.W. Do biomaterials cause implant-associated mesenchymal tumors of the breast? Analysis of 8 new cases and review of the literature. Hum Pathol 2009, 40:1564-1570.
9. Engel A., Lamm S.H., Lai S.H. Human breast sarcoma and human breast implantation: a time trend analysis based on SEER data (1973-1990). J Clin Epidemiol 1995, 48:539-544.
10. Yap J., Chuba P.J., Thomas R., Aref A., Lucas D., Severson R.K., et al. Sarcoma as a second malignancy after treatment for breast cancer. Int J Rad Oncol Biol Phys 2002, 52:1231-1237.
11. Kirova Y.M., Vilcoq J.R., Asselain B., Sastre-Garau X., Fourquet A. Radiation-induced sarcomas after radiotherapy for breast carcinoma. Cancer 2005, 104:856-863.
12. Erel E., Vlachou E., Athanasiadou M., Hassan S., Chandrasekar C.R., Peart F. Management of radiation-induced sarcomas in a tertiary referral centre: a review of 25 cases. Breast 2010, 19:424-427.
13. Scow J.S., Reynolds C.A., Degnim A.C., Petersen I.A., Jakub J.W., Boughey J.C. Primary and secondary angiosarcoma of the breast: the Mayo clinic experience. J Surg Oncol 2010, 101:401-407.
14. Luini A., Gatti G., Diaz J., Botteri E., Oliveira E., Cecilio Sahium de Almeida R., et al. Angiosarcoma of the breast: the experience of the European Institute of Oncology and a review of the literature. Breast Cancer Res Treat 2007, 105:81-85.
15. Nakamura R., Nagashima T., Sakakibara M., Nakano S., Tanabe N., Fujimoto H., et al. Angiosarcoma arising in the breast following breast-conserving surgery with radiation for breast carcinoma. Breast Cancer 2007, 14:245-249.
16. Lai M.H.Y., Lui C.Y. Mammary angiosarcoma in two patients at either end of age spectrum. Hong Kong Med J 2010, 16:141-144.
17. Hodgson N.C., Bowen-Wells C., Moffat F., Franceschi D., Avisar E. Angiosarcoma of the breast. A review of 70 cases. Am J Clin Oncol 2007, 30:570-573.
18. Wang X.Y., Jakowski J., Tawfik O.W., Thomas P.A., Fan F. Angiosarcoma of the breast: a clinicopathologic analysis of cases from the last 10 years. Ann Diagn Pathol 2009, 13:147-150.
19. Lucas D.R. Angiosarcoma, radiation-associated angiosarcoma, and atypical vascular lesion. Arch Pathol Lab Med 2009, 133:1804-1809.
20. Vautravers C., Dewas S., Truc G., Penel N. Sarcomes en territoire irradié: actualités. Cancer Radiothér 2010, 14:74-80.
21. Bahrami A., Resetkova E., Ro J.Y., Ibañez J.D., Ayala A.G. Primary osteosarcoma of the breast. Report of 2 cases. Arch Pathol Lab Med 2007, 131:792-795.
22. Murakami S., Isozaki H., Shou T., Sakai K., Yamamoto Y., Oomori M., et al. Primary osteosarcoma of the breast. Pathol Int 2009, 59:111-115.
23. Silver S.A., Tavassoli F.A. Primary osteogenic sarcoma of the breast: a clinicopathological analysis of 50 cases. Am J Surg Pathol 1998, 22:925-933.
24. Khan S., Griffiths E.A., Shah N., Ravi S. Primary osteogenic sarcoma of the breast: a case report. Cases J 2008, 1:148.
25. Lum Y.W., Jacobs L. Primary breast sarcoma. Surg Clin N Am 2008, 88:559-570.
26. Yang W.T., Hennessy B.T., Dryden M.J., Valero V., Hunt K.K., Krishnamurthy S. Mammary angiosarcomas: imaging findings in 24 patients. Radiol 2007, 242:725-734.
27. AJCC (American Joint Committee on Cancer) Cancer staging manual 2010, Springer, New York. 7th ed. S.B. Edge, D.R. Byrd, C.C. Compton, A.G. Fritz, F.L. Greene, A. Trotti (Eds.).
28. Williamson D., Missiaglia E., de Reyniès A., Pierron G., Thuille B., Palenzuela G., et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol 2010, 28:2151-2158.
29. Kawai A., Woodruff J., Healey J.H., Brennan M.F., Antonescu C.R., Ladanyi M. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 1998, 338:153-160.
30. Ladanyi M., Antonescu C.R., Leung D.H., Woodruff J.M., Kawai A., Healey J.H., et al. Impact of SYT-SXX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 343 patients. Cancer Res 2002, 62:135-140.
31. Sun Y., Sun B., Wang J., Cai W., Zhao X., Zhang S., et al. Prognostic implication of SYT-SSX fusion type and clinicopathological parameters for tumor-related death, recurrence, and metastasis in synovial sarcoma. Cancer Sci 2009, 100:1018-1025.
32. Guillou L., Benhattar J., Bonichon F., Gallagher G., Terrier P., Stauffer E., et al. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol 2004, 22:4040-4050.
33. ten Heuvel S.E., Hoekstra H.J., Bastiaannet E., Suurmeijer A.J.H. The classic prognostic factors tumor stage, tumor size, and tumor grade are the strongest predictors of outcome in synovial sarcoma. No role for SXX fusion type or ezrin expression. Appl Immunohistochem Mol Morphol 2009, 17:189-195.
34. Takenaka S., Ueda T., Naka N., Araki N., Hashimoto N., Myoui A., et al. Prognostic implication of SYT-SSX fusion type in synovial sarcoma: a multi-institutional retrospective analysis in Japan. Oncol Rep 2008, 19:467-476.
35. Oliveira A.M., Fletcher C.D.M. Molecular prognostication for soft tissue sarcomas: are we ready yet?. J Clin Oncol 2004, 22:4031-4034.
36. Yoshitani K., Kido A., Honoki K., Fujii H., Takakura Y. Pelvic metastasis of breast synovial sarcoma. J Orthop Sci 2009, 14:219-223.
37. Tormo V., Andreu F.J. Primary breast synovial sarcoma: a rare primary breast neoplasia. Clin Transl Oncol 2009, 11:854-855.
38. de Vreeze R.S.A., de Jong D., Tielen I.H.G., Ruijter H.J., Nederlof P.M., Haas R.L., et al. Primary retroperitoneal myxoid/round cell liposarcoma is a nonexisting disease: an immunohistochemical and molecular biological analysis. Mod Pathol 2009, 22:223-231.
39. Tunon de Lara C., Roussillon E., Rivel J., Maugey-Laulom B., Alfonso A.-L., Horovitz J. Liposarcome du sein. Apropos d'un cas. J Gynecol Obstet Biol Reprod 1998, 27:201-204.
40. Charfi L., Driss M., Mrad K., Abbes I., Dhouib R., Sassi S., et al. Primary well differentiated liposarcoma: an unusual tumor in the breast. Breast J 2009, 15:206-207.
41. Egger J.-F., Coindre J.-M., Benhattar J., Coucke P., Guillou L. Radiation-associated synovial sarcoma: clinicopathologic and molecular analysis of two cases. Mod Pathol 2002, 15:998-1004.
42. Zelek L., Llombart-Cussac A., Terrier P., Pivot X., Guinebretiere J.M., Le Pechoux C., et al. Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-up. J Clin Oncol 2003, 21:2583-2588.
43. Blanchard D.K., Reynolds C.A., Grant C.S., Donohue J.H. Primary nonphylloides breast sarcomas. Am J Surg 2003, 186:359-361.
44. Gladdy R.A., Qin L.-X., Moraco N., Edgar M.A., Antonescu C.R., Alektiar K.M., et al. Do radiation-associated soft tissue sarcomas have the same prognosis as sporadic soft tissue sarcomas?. J Clin Oncol 2010, 28:2064-2069.
45. Cha C., Antonescu C.R., Quan M.L., Maru S., Brennan M.F. Long-term results with resection of radiation-induced soft tissue sarcomas. Ann Surg 2004, 239:903-910.
46. Al-Benna S., Poggemann K., Steinau H.-U., Steinstraesser L. Diagnosis and management of primary breast sarcoma. Breast Cancer Res Treat 2010, 122:619-626.
47. Barrow B.J., Janjan N.A., Gutman H., Benjamin R.S., Allen P., Romsdahl M.M., et al. Role of radiotherapy in sarcoma of the breast - a retrospective review of the M.D. Anderson experience. Radiother Oncol 1999, 52:173-178.
48. Sher T., Hennessy B.T., Valero V., Broglio K., Woodward W.A., Trent J., et al. Primary angiosarcomas of the breast. Cancer 2007, 110:173-178.
49. Zeng W., Styblo T.M., Li S., Sepulveda J.N., Schuster D.M. Breast angiosarcoma. FDG PET findings. Clin Nucl Med 2009, 34:443-445.
50. Reynoso D., Subbiah V., Trent J.C., Guadagnolo B.A., Lazar A.J., Benjamin R., et al. Neoadjuvant treatment of soft-tissue sarcoma: a multimodality approach. J Surg Oncol 2010, 101:327-333.
51. Grimer R., Judson I., Peake D., Seddon B. Guidelines for the management of soft tissue sarcomas. Sarcoma 2010, Article ID 506182: 15 pages.
52. Santoro A., Tursz T., Mouridsen H., Verweij J., Steward W., Somers R., et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995, 13:1537-1545.
53. Le Cesne A., Antoine E., Spielmann M., Le Chevalier T., Brain E., Toussaint C., et al. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995, 13:1600-1608.
54. Maki R.G., Wathen J.K., Patel S.R., Priebat D.A., Okuno S.H., Samuels B., et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol 2007, 25:2755-2763.
55. Leu K.M., Ostruszka L.J., Shewach D., Zalupski M., Sondak V., Biermann J.S., et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 2004, 22:1706-1712.
56. Dileo P., Morgan J.A., Zahrieh D., Desai J., Salesi J.M., Harmon D.C., et al. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. Cancer 2007, 109:1863-1869.
57. Le Cesne A., Blay J.Y., Judson I., Van Oosterom A., Verweij J., Radford J., et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organization for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005, 23:576-584.
58. DiLeo P., Sanfilippo R., Grosso F., Fumagalli E., Blay J., Domont J., et al. Trabectedin (T) in advanced, pretreated synovial sarcomas (SS): a retrospective analysis of 39 patients (pts) from three European institutions. J Clin Oncol 2010, 28(suppl). 705s (abstr. 10030).
59. Skubitz K.M., Haddad P.A. Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer 2005, 104:361-366.
60. Penel N., Bui B.N., Bay J.-O., Cupissol D., Ray-Coquard I., Piperno-Neumann S., et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX study. J Clin Oncol 2008, 26:5269-5274.
61. Mano M.S., Fraser G., Kerr J., Gray M., Evans V., Kazmi A., et al. Radiation-induced angiosarcoma of the breast shows major response to docetaxel after failure of anthracycline-based chemotherapy. Breast 2006, 15:117-118.
62. Perez-Ruiz E., Ribelles N., Sanchez-Muñoz A., Roman A., Marquez A. Response to paclitaxel in a radiotherapy-induced breast angiosarcoma. Acta Oncol 2009, 48:1078-1079.
63. Neuhaus S.J., Pinnock N., Giblin V., Fisher C., Thway K., Thomas J.M., et al. Treatment and outcome of radiation-induced soft-tissue sarcomas at a specialist institution. Eur J Surg Oncol 2009, 35:654-659.
64. des Guetz G., Chapelier A., Mosseri V., Dorval T., Asselain B., Pouillart P. Postirradiation sarcoma: clinicopathologic features and role of chemotherapy in the treatment strategy. Sarcoma 2009, Article ID 764379: 5 pages.
65. Palta M., Morris C.G., Grobmyer S.R., Copeland E.M., Mendenhall N.P. Angiosarcoma after breast-conserving therapy. Cancer 2010, 116:1872-1878.
66. Verschraegen C.F., Chawla S.P., Mita M.M., Ryan C.W., Blakely L., Keedy V.L., et al. A phase II, randomized, controlled trial of palifosfamide plus doxorubicin versus doxorubicin in patients with soft tissue sarcoma (PICASSO). J Clin Oncol 2010, 28(suppl). 699s (abstr. 10004).
67. Schoffski P., Ray-Coquard I.L., Cioffi A., Bin Bui N., Bauer S., Hartmann J.T., et al. Activity of eribulin mesylate (E7389) in patients with soft tissue sarcoma (STS): phase II studies of the European Organisation for research and treatment of cancer soft tissue and bone sarcoma group (EORTC 62052). J Clin Oncol 2010, 28(suppl). 705s (abstr. 10031).
68. Verweij J., van Oosterom A., Blay J.-Y., Judson I., Rodenhuis S., van der Graaf W., et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003, 39:2006-2011.
69. Blay J.-Y., von Mehren M., Blackstein M.E. Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors. Cancer 2010 Jul 26, [e-pub ahead of print].
70. Yudoh K., Kanamori M., Ohmori K., Yasuda T., Aoki M., Kimura T. Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas. Br J Cancer 2001, 84:1610-1615.
71. Antonescu C.R., Yoshida A., Guo T., Chang N.-E., Zhang L., Agaram N.P., et al. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res 2009, 69:7175-7179.
72. Ganjoo K.N. New developments in targeted therapy for soft tissue sarcoma. Curr Oncol Rep 2010, 12:261-265.
73. Schutz F.A.B., Choueiri T.K., Sternberg C.N. Pazopanib: clinical development of a potent anti-angiogenic drug. Crit Rev Oncol Hematol 2010, April 22, [e-pub ahead of print].
74. Sleijfer S., Ray-Coquard I., Papai Z., Le Cesne A., Scurr M., Schöffski P., et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC study 62043). J Clin Oncol 2009, 27:3126-3132.
75. Jiang B.H., Agani F., Passaniti A., Semenza G.L. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 1997, 57:5328-5335.
76. Schuetze S., Wathen K., Choy E., Samuels B.L., Ganjoo K.N., Staddon A.P., et al. Results of a Sarcoma Alliance for Research through Collaboration (SARC) phase II trial of dasatinib in previously treated, high-grade, advanced sarcoma. J Clin Oncol 2010, 28(suppl). 700s (abstr. 10009).
77. Olmos D., Tan D.S.W., Jones R.L., Judson I.R. Biological rationale and current clinical experience with anti-insulin-like Growth Factor 1 Receptor monoclonal antibodies in treating sarcoma. Cancer J 2010, 16:183-194.
78. Olmos D., Postel-Vinay S., Molife L.R. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol 2010, 11:129-135.
79. Richter S., Pink D., Hohenberger P., Schuette H., Casali P.G., Pustowka A., et al. Multicenter, triple-arm, single-stage, phase II trial to determine the efficacy and safety of everolimus (RAD001) in patients with refractory bone or soft tissue sarcomas including GIST. J Clin Oncol 2010, 28(suppl). 707s (abstr. 10038).
80. Quek R.H., Morgan J.A., Shapiro G., Butrynski J.E., Wang Q., Huftalen T., et al. Combination mTOR+IR inhibition: phase I trial of everolimus and CP-751871 in patients (pts) with advanced sarcomas and other solid tumors. J Clin Oncol 2010, 28(suppl). 698s (abstr. 10002).
81. Reed D.R., Brazelle W., Gemmer J., Altiok S. Targeting CHK1 pathway to induce cytotoxic response to histone deacetylase inhibitors and evaluating the synergistic effects of CHK1 and HDAC inhibitors in human soft tissue sarcoma cell lines and primary tumor xenografts. J Clin Oncol 2010, 28(suppl). 710s (abstr. 10049).
82. Garcia del Muro X., Lopez-Pousa A., Martin Broto J., Cubedo R., Jimenez Colomo L., Gallego O., et al. Phase I study of sorafenib plus ifosfamide in patients with advanced soft tissue and bone sarcoma: a Spanish Group for Research on Sarcomas (GEIS) study. J Clin Oncol 2010, 28(suppl). 704s (abstr. 10024).